Reviva Pharmaceuticals Q3 2026 net loss narrows 43% to $2.3 million
RVPH•Reviva Pharmaceuticals’ third-quarter 2026 net loss narrowed 43% year over year to $2.3 million, while operating expenses fell 40% to $2.43 million. Cash and cash equivalents were $17.46 million at September 30, 2026, up 21% from December 31, 2025.
1. Quarterly results
Reviva Pharmaceuticals’ third-quarter 2026 net loss narrowed 43% year over year to $2.3 million. Operating expenses fell 40% to $2.43 million, and cash and cash equivalents rose 21% to $17.46 million at September 30, 2026, from December 31, 2025.
2. Trial timeline
The company expects FDA feedback in the fourth quarter of 2026 on a proposed new brilaroxazine formulation for the RECOVER-2 trial. It is targeting RECOVER-2 Phase 3 patient enrollment in the first half of 2027, subject to additional financing.
